179929-91-0Relevant academic research and scientific papers
NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION
-
Paragraph 0188, (2021/03/18)
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurode
SELECTIVE BETA 3 ADRENERGIC AGONISTS
-
, (2008/06/13)
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: STR1
Selective beta3 adrenergic agonists
-
, (2008/06/13)
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and
